mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients.

Study MOTIF : mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients

The injuries induced by Human Papillomavirus (HPV) (anogenital condyloma mainly) are more frequent among transplanted patients due to their immunosuppression. These injuries are benign but they have a negative impact on the patients' quality of life. The initial treatment is topical and then surgical. The injuries can relapse, especially among transplanted patients.

The modification of the immunosuppressant treatment with a switch to mTOR inhibitors (mammalian Target Of Rapamycin) has shown its efficacy in preventing the recurrence of squamous cell carcinomas or treating Kaposi's disease.

By analogy, this therapeutic strategy can be sometimes put forward to transplanted patients with HPV-induced injuries.

The principal objective of this study is to describe the evolution of HPV-induced lesions in solid organ transplant patients.

Inclusion Criteria:

• Adult patient (Age ≥ 18 years)
• Transplanted patient (any organ), having developed HPV-induced lesions after transplantation
• Patient followed or having been followed at Edouard Herriot Hospital (HEH)
• Patient having been informed and not having objected to participating in the study

Exclusion Criteria:

• Transplanted patient without HPV-induced lesions